[Skip to Navigation]
Sign In
From The Medical Letter on Drugs and Therapeutics
September 22/29, 2015

Alirocumab (Praluent) to Lower LDL-Cholesterol

JAMA. 2015;314(12):1284-1285. doi:10.1001/jama.2015.11372

The FDA has approved the subcutaneously injected PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor alirocumab (Praluent – Sanofi/Regeneron) as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol (LDL-C) (Box). It was not approved for general use in statin-intolerant patients. Alirocumab is the first PCSK9 inhibitor to be approved in the US. Evolocumab (Repatha – Amgen), another PCSK9 inhibitor, was recently approved in Europe and has been recommended for approval for the same indications in the US by an FDA Advisory Committee.

Add or change institution